

- Clinical effects of the glucagon-like peptide 1 (GLP-1) receptor agonist liraglutide were examined through a retrospective analysis of a real-life Health Maintenance Organization (HMO) cohort.
- After 6 months, glycated haemoglobin (A1c) decreased by a mean of 9 mmol/mol in 933 patients with data available.
- In 453 patients with data available, weight decreased by a mean of 2.55 kg.
- Clinical effects of liraglutide in a real-life cohort of patients with type 2 diabetes were similar to those reported in clinical trials.

This summary slide represents the opinions of the authors. Sponsorship for this study was funded by Novo Nordisk, Region International Operations A/S Zurich Switzerland. Medical writing assistance for this study was provided by Jenna Steere of Watermeadow Medical (Oxford, UK). For a full list of acknowledgments and conflicts of interest for all authors of this article, please see the full text online. Copyright © The Authors 2014. Creative Commons Attribution Noncommercial License (CC BY-NC).